10/23/2022 0 Comments Hasten death![]() ![]() T1 - Palliative sedation therapy does not hasten death Conclusion: PST does not shorten life when used to relieve refractory symptoms and does not need the doctrine of double effect to justify its use from an ethical point of view.", Median survival of arm A was 12 days, while that of arm B was 9 days (90% CI 8-10) (log rank = 0.95, P = 0.330) (unadjusted hazard ratio = 0.92, 90% CI 0.80-1.06). Mean and median duration of sedation was 4 (standard deviation 6.0) and 2 days (range 0-43), respectively. In total, 25.1% of patients admitted to the participating hospices received PST. Results: Of the 518 patients enrolled, 267 formed cohort A and 251 cohort B. Cohorts were matched for age class, gender, reason for hospice admission, and Karnofsky performance status. Methods: This multicenter, observational, prospective, nonrandomized population-based study evaluated overall survival in two cohorts of hospice patients, one submitted to palliative sedation (A) and the other managed as per routine hospice practice (B). We aimed to evaluate whether PST has a detrimental effect on survival in terminally ill patients. Conclusion: PST does not shorten life when used to relieve refractory symptoms and does not need the doctrine of double effect to justify its use from an ethical point of view.Ībstract = "Background: Palliative sedation therapy (PST) is indicated for and used to control refractory symptoms in cancer patients undergoing palliative care. ![]() Background: Palliative sedation therapy (PST) is indicated for and used to control refractory symptoms in cancer patients undergoing palliative care. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |